Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating

Maxwell Skor, an analyst from Morgan Stanley, has initiated a new Buy rating on Insmed (INSM).

Maxwell Skor has given his Buy rating due to a combination of factors that highlight Insmed’s strategic positioning and growth potential. One of the primary reasons is the anticipated approval and launch of brensocatib, which could become the first approved therapy for bronchiectasis. This development is expected to significantly boost the company’s value, especially with the FDA’s recent indication that there will be no Advisory Committee meeting, which is seen as a positive sign for approval.
Additionally, Insmed’s existing product, Arikayce, has shown robust sales growth, with 2024 marking its highest quarterly sales to date. The company has also provided strong guidance for 2025, expecting continued revenue growth. Furthermore, Insmed’s pipeline remains promising with upcoming clinical readouts for TPIP and other trials, suggesting sustained long-term growth potential. These factors collectively underpin Maxwell Skor’s optimistic outlook and Buy rating for Insmed’s stock.

In another report released yesterday, UBS also maintained a Buy rating on the stock with a $110.00 price target.

INSM’s price has also changed slightly for the past six months – from $71.040 to $75.020, which is a 5.60% increase.